Drugmakers Must Redo Research After FDA Finds Problems With Contractor
The FDA found "objectionable conditions" during a 2023 inspection of the Raptim Research facility in Nava Mumbai, India. An unspecified number of companies are affected. Raptim said on its website that the FDA recently inspected an unnamed facility and didn't find problems; it's unclear when that inspection occurred.